Grail this week announced a presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago describing a study design for its Galleri multicancer early detection (MCED) blood test.
The NHS-Galleri study is a randomized and controlled clinical trial in the U.K. National Health Service's clinical practice setting.
It is among the largest studies for an MCED test, according to Grail, enrolling 140,000 healthy volunteers ages 50 to 77 in select regions throughout England who have not had a cancer diagnosis or undergone treatment for cancer in the last three years.
The study design was described in a poster presentation at ASCO by Dr. Charles Swanton, MD, PhD, a cancer researcher and oncologist at University College London.
The Galleri test detects abnormalities in the methylation patterns of cell-free DNA (cfDNA) that could indicate the presence of cancer.
